Insider · CIK 0001949621

Eizen Joshua M

Reports to the SEC for 1 company · MENLO PARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001949621

Forms 4 and 5

Insider transactions

21 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-07-08	ANTXAN2 Therapeutics, Inc.S Sale	See Remarks	SSale	−5,945 sh	$4.17	−$24.8K	206,554
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	See Remarks	AAward	+92K sh	—	—	92,000
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	See Remarks	DDisposition to Issuer	−92K sh	—	—	0
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	See Remarks	AAward	+50.2K sh	—	—	50,150
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	See Remarks	DDisposition to Issuer	−50.2K sh	—	—	0
2026-02-20	ANTXAN2 Therapeutics, Inc.A Award	See Remarks	AAward	+50K sh	—	—	207,499
2026-02-20	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	See Remarks	AAward	+100K sh	—	—	100,000
2026-01-06	ANTXAN2 Therapeutics, Inc.S Sale	See Remarks	SSale	−6,931 sh	$1.01	−$7,014.172	152,499
2026-01-05	ANTXAN2 Therapeutics, Inc.S Sale	See Remarks	SSale	−17.9K sh	$1.00	−$17.9K	159,430
2025-11-04	ANTXAN2 Therapeutics, Inc.S Sale	See Remarks	SSale	−2,819 sh	$1.14	−$3,213.66	177,353
2025-02-26	ANTXAN2 Therapeutics, Inc.A Award	See Remarks	AAward	+58.5K sh	—	—	175,172
2025-02-26	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	See Remarks	AAward	+117K sh	—	—	117,000
2025-01-03	ANTXAN2 Therapeutics, Inc.S Sale	See Remarks	SSale	−9,663 sh	$1.34	−$13K	116,672
2024-11-04	ANTXAN2 Therapeutics, Inc.A Award	See Remarks	AAward	+31.5K sh	—	—	126,335
2024-11-04	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	See Remarks	AAward	+63K sh	—	—	63,000
2024-07-10	ANTXAN2 Therapeutics, Inc.A Award	See Remarks	AAward	+60K sh	—	—	94,833
2024-03-15	ANTXAN2 Therapeutics, Inc.A Award	See Remarks	AAward	+30K sh	—	—	32,447
2024-03-15	ANTXAN2 Therapeutics, Inc.A Award	See Remarks	AAward	+30K sh	—	—	32,447
2024-03-15	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	See Remarks	AAward	+60K sh	—	—	60,000
2023-02-15	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	See Remarks	AAward	+50.2K sh	—	—	50,150
2022-10-14	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	See Remarks	AAward	+92K sh	—	—	92,000

Recent filings

Accepted (ET)
Jul 104
Eizen Joshua M0001193125-26-301092
SEC(opens sec.gov)
Mar 234
Eizen Joshua M0001193125-26-120210
SEC(opens sec.gov)
Feb 234
Eizen Joshua M0001193125-26-064176
SEC(opens sec.gov)
Jan 74
Eizen Joshua M0001193125-26-006763
SEC(opens sec.gov)
Nov 64
Eizen Joshua M0001193125-25-270255
SEC(opens sec.gov)
Feb 284
Eizen Joshua M0000950170-25-030042
SEC(opens sec.gov)
Jan 74
Eizen Joshua M0000950170-25-003152
SEC(opens sec.gov)
Nov 54
Eizen Joshua M0000950170-24-121591
SEC(opens sec.gov)
Jul 124
Eizen Joshua M0000950170-24-083200
SEC(opens sec.gov)
Mar 294/A
Eizen Joshua M0001610717-24-000194
SEC(opens sec.gov)
Mar 184
Eizen Joshua M0001610717-24-000168
SEC(opens sec.gov)
Feb 174
Eizen Joshua M0000899243-23-005554
SEC(opens sec.gov)

Companies

AN2 Therapeutics, Inc.See RemarksANTX

Address

C/O AN2 THERAPEUTICS, INC. 1300 EL CAMINO REAL, SUITE 100

MENLO PARK, CA, 94025